-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Chengdu Yuandong Biotechnology has entered the administrative examination and approval stage with the imitation of four types of propofol fumarate tablets and dabigatran etexilate capsules, and approval will be imminent.
Yuandong Biological is approving varieties
Source: Meinenet MED2.
Profol tenofovir (Vemlidy) is a powerful antiviral drug developed by Gilead for the treatment of chronic hepatitis B in adults and adolescents.
According to data from Mynet, the terminal sales of propofol tenofovir in China's public medical institutions in 2020H1 exceeded 100 million yuan, a year-on-year increase of 1952.
Dabigatran etexilate belongs to the β-alanine thrombin inhibitor, which is converted into dabigatran with direct anticoagulant activity in the body after oral absorption through the gastrointestinal tract.
Sales of terminal dabigatran etexilate in public medical institutions in China
Source: Mi Nei.
According to data from Menet.
Currently, Dabigatran Etexilate Capsules have been approved for production by 3 domestic companies, including Chia Tai Tianqing Pharmaceutical Group, Jiangsu Hausen Pharmaceutical, and Chengdu Better Pharmaceutical.
Source: Minet database